Computational Cancer Pharmacologist | Postdoctoral Researcher at UNC Chapel Hill
Chapel Hill, NC
Joined February 2018
- Tweets333
- Following437
- Followers259
- Likes2K
Pinned Tweet
I've developed a model of combination chemotherapy and trained it on DLBCL trials. The ultimate test of my model is to predict new trial results, so I predicted the results of the POLARIX trial. Today I got to check the predictions, and they were right!
bit.ly/3yuf0MC
Dr. Amy Pomeroy retweeted
It's postdoc appreciation week: I'm grateful for my lab's first postdoc @AmyEPomeroy - author of so many great papers on combination cancer pharmacology it needs a thread:
Drug independence and the curability of cancer by combination chemotherapy
doi.org/10.1016/j.trecan.202…
1/n
Feeling very appreciated! I am so thankful for @ac_palmer's mentorship throughout my postdoc. I'm really proud of what we've accomplished!
It's postdoc appreciation week: I'm grateful for my lab's first postdoc @AmyEPomeroy - author of so many great papers on combination cancer pharmacology it needs a thread:
Drug independence and the curability of cancer by combination chemotherapy
doi.org/10.1016/j.trecan.202…
1/n
Dr. Amy Pomeroy retweeted
Spotlight: Antifragility in Cancer!
@AmyEPomeroy & @ac_palmer wrote a Spotlight highlighting our recent mansucript on antifragile therapy dosing strategies in Cancer Research:
Dr. Amy Pomeroy retweeted
'Less is more' maintenance therapy in #MultipleMyeloma!
Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg)
Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence
Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs!
However, with quad induction + MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets!
tinyurl.com/8thww4sz
Dr. Amy Pomeroy retweeted
A very well-written and thoughtful piece from Itai Yanai and Martin Lercher, with a nice visual showing how we “trim the tree” of the process, for publication.
On a related note, I’d like to see more Math Onco papers show the discovery process within papers — e.g. the process of model selection!
Dr. Amy Pomeroy retweeted
i'm just a senior postdoc, standing in front of a career that i have worked really hard for, asking higher education in the united states to not completely implode in front of my eyes before i even get a chance to say the words 'my lab studies'
Dr. Amy Pomeroy retweeted
Congrats to Drs. Amy Pomeroy @AmyEPomeroy and Adam Palmer @ac_palmer! They published a mathematical model on multi-drug therapy with clinical implications that address tumor and patient heterogeneity in drug sensitivity!
Read more through @BCD_AACR:
aacrjournals.org/bloodcancer…
ALT Patients vary in their sensitivity to different drugs. Source: Pomeroy, A. E., & Palmer, A. C. (2025). Blood cancer discovery.
Dr. Amy Pomeroy retweeted
Congratulations @ac_palmer @AmyEPomeroy !!! Fantastic to see this work out!
Dr. Amy Pomeroy retweeted
New paper by @AmyEPomeroy!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out now in Blood Cancer Discovery @BCD_AACR
doi.org/10.1158/2643-3230.BC…
#mathonc #lymsm #BloodCancer
1/n
Dr. Amy Pomeroy retweeted
First author Amy Pomeroy presents her recently published work in Blood Cancer Discovery: A model of curative combination therapy for lymphoma by @amyEpomeroy and @ac_palmer.
Read the article: brnw.ch/21wRb8A
Dr. Amy Pomeroy retweeted
Dr. Amy Pomeroy @AmyEPomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
Dr. Amy Pomeroy retweeted
New de-novo TCR design preprint from @DhuviKarthikey1 just dropped:
TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences
biorxiv.org/content/10.1101/…
Dr. Amy Pomeroy retweeted
Kudos to @brian_rini for accurately describing the effects of combination therapies :)
Thank you @TIME for highlighting our work in Kidney Cancer at @DanaFarber and @DanaFarber_GU
time.com/7018184/kidney-canc…
Dr. Amy Pomeroy retweeted
📌 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Great talk by @LoiSher @OncoAlert #ASCO24 #BreastCancer
✔️the largest study
➡️8% positive for ctDNA at baseline
➡️ ctDNA detection was highly prognostic of worse outcomes, particularly for patients who were persistently positive
Dr. Amy Pomeroy retweeted
Common Sense Oncology chapter is now live in ASCO Ed Book. Check it out.
ascopubs.org/doi/pdf/10.1200…
We also have a @csoncol session at #ASCO24 Monday morning 8AM!
The UNC System has been doing DEI for as long as I can remember. North Carolina is a diverse state with multiple metropolitan counties (Wake, Mecklenburg, etc.) and many more rural counties (Edgecombe, Wataguga, etc.). Enrollment at UNC reflects that diversity.
Example: In the same biology class you will find two students: one took AP chemistry and the other came from a school that didn't have a chemistry teacher. Both deserved to be there but the latter would have been excluded without DEI initiatives (and inclusive teaching practices)